ONCAlert | 2018 ASCO Annual Meeting
Videos  >  

The Significance of Results for Entrectinib in ROS1+ NSCLC

Robert C. Doebele, MD, PhD
Published Online:8:12 PM, Mon October 23, 2017

Robert C. Doebele, MD, PhD, associate professor, Division of Medical Oncology, University of Colorado, discusses the significance of the results of a trial exploring entrectinib in patients with ROS1-positive non–small cell lung cancer (NSCLC).
Copyright © TargetedOnc 2018 Intellisphere, LLC. All Rights Reserved.